|  | CYP26A1 expression |  | |
---|---|---|---|---|
Variables | Cases (n) | Negative (%) | Positive (%) | P |
Age (years) | Â | Â | Â | Â |
  <60 | 59 | 31 (52.5) | 28 (47.5) | 0.136 |
  ≥60 | 61 | 41 (67.2) | 20 (32.8) |  |
Sex | Â | Â | Â | Â |
  Male | 104 | 61 (58.7) | 43 (41.3) | 0.586 |
  Female | 16 | 11 (68.8) | 5 (31.2) |  |
Primary tumor status (pT) | Â | Â | Â | Â |
  pT1 | 9 | 6 (66.7) | 3 (33.3) | 0.025* |
  pT2 | 38 | 25 (65.8) | 13 (34.2) |  |
  pT3 | 35 | 25 (71.4) | 10 (28.6) |  |
  pT4 | 34 | 13 (38.2) | 21 (61.8) |  |
Lymph node involvement (pN) | Â | Â | Â | Â |
  Absent | 65 | 40 (61.5) | 25 (38.5) | 0.574 |
  Present | 52 | 29 (55.8) | 23 (44.2) |  |
Distant metastasis (M) | Â | Â | Â | Â |
  Absent | 115 | 69 (60.0) | 46 (40.0) | 1.000 |
  Present | 4 | 2 (50.0) | 2 (50.0) |  |
pTNM stage | Â | Â | Â | Â |
  pStage I | 7 | 5 (71.4) | 2 (28.6) | 0.015* |
  pStage II | 26 | 18 (69.2) | 8 (30.8) |  |
  pStage III | 35 | 26 (74.3) | 9 (25.7) |  |
  pStage IV | 49 | 21 (42.9) | 28 (57.1) |  |